ArticleCancer immunology, immunotherapy : CII2007
Induction of tumor-specific T-cell responses by vaccination with tumor lysate-loaded dendritic cells in colorectal cancer patients with carcinoembryonic-antigen positive tumors.
Article in Cancer immunology, immunotherapy : CII, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Clinical outcomes of active specific immunotherapy in advanced colorectal cancer and suspected minimal residual colorectal cancer: a meta-analysis and system review.Journal of translational medicine · 2011Pooled it
- A randomized trial of ex vivo CD40L activation of a dendritic cell vaccine in colorectal cancer patients: tumor-specific immune responses are associated with improved survival.Clinical cancer research : an official journal of the American Association for Cancer Research · 2010Trial
- Dendritic cells: the central partner for cancer immunity.Oncoimmunology · 2025Review
- Dendritic cells loaded with exosomes derived from cancer stem cell-enriched spheroids as a potential immunotherapeutic option.Journal of cellular and molecular medicine · 2021Article
- Induction of Antitumor Immunity by Exosomes Isolated from Cryopreserved Cord Blood Monocyte-Derived Dendritic Cells.International journal of molecular sciences · 2020Article
- Dendritic cell-based cancer immunotherapy for colorectal cancer.World journal of gastroenterology · 2016Review
- In vitro-activated tumor-specific T lymphocytes prolong the survival of patients with advanced gastric cancer: a retrospective cohort study.OncoTargets and therapy · 2016Article
- Clinical significance of immunotherapy with combined three kinds of cells for operable colorectal cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Trial watch: Dendritic cell-based interventions for cancer therapy.Oncoimmunology · 2012Article
- Poly(I:C)-induced tumour cell death leads to DC maturation and Th1 activation.Cancer immunology, immunotherapy : CII · 2011Article
- Therapeutic vaccines for gastrointestinal cancers.Gastroenterology & hepatology · 2011Article
- Tumor cell lysate-pulsed dendritic cells induce a T cell response against colon cancer in vitro and in vivo.Medical oncology (Northwood, London, England) · 2010Article
- A novel cancer vaccine strategy based on HLA-A*0201 matched allogeneic plasmacytoid dendritic cells.PloS one · 2010Article
- Protective anti-tumour immune responses by murine dendritic cells pulsed with recombinant Tat-carcinoembryonic antigen derived from Escherichia coli.Clinical and experimental immunology · 2009Article
- Effects of herpes simplex virus amplicon transduction on murine dendritic cells.Human gene therapy · 2009Article
- Immunotherapy for liver tumors: present status and future prospects.Journal of biomedical science · 2009Review
- Clinical-scale generation of human anti-Aspergillus T cells for adoptive immunotherapy.Bone marrow transplantation · 2009Article
- Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines.Cancer immunology, immunotherapy : CII · 2008Review
- CpG-ODN but not other TLR-ligands restore the antitumor responses in old mice: the implications for vaccinations in the aged.Cancer immunology, immunotherapy : CII · 2008Article
- Vγ9γδ T Cell Induction by Human Umbilical Cord Blood Monocytes-Derived, Interferon-α-Stimulated Dendritic Cells.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundDendritic cells (DCs) are the most effective antigen-presenting cells. In the last decade, the use of DCs for immunotherapy of cancer patients has been vastly increased. High endocytic capacity together with a unique capability of initiating primary T-cell responses have made DCs the most potent candidates for this purpose. Although DC vaccination occasionally leads to tumor regression, clinical efficacy, and immunogenicity of DCs in clinical trials has not been yet clarified. The present study evaluated the safety and effectiveness of tumor-lysate loaded DC vaccines in advanced colorectal cancer (CRC) patients with carcinoembryonic antigen (CEA) positive tumors.
resultsSix patients HLA-A*0201-positive were vaccinated with autologous DCs loaded with tumor lysates (TL) together with tetanus toxoid antigen, hepatitis B, and influenza matrix peptides. Two additional patients were injected with DCs that were generated from their sibling or parent with one haplotype mismatch. All patients received the vaccines every 2 weeks, with a total of three intra-nodal injections per patient. The results indicated that DC vaccination was safe and well tolerated by the patients. Specific immune responses were detected and in some patients, transient stabilization or even reduction of CEA levels were observed. The injection of haplotype mismatched HLA-A*0201-positive DCs resulted in some enhancement of the anti-tumor response in vitro and led to stabilization/reduction of CEA levels in the serum, compared to the use of autologous DCs.
conclusionAltogether, these results suggest that TL-pulsed DCs may be an effective vaccine method in CRC patients. Elimination of regulatory mechanisms as well as adjustment of the vaccination protocol may improve the efficacy of DC vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.